News FDA fast-tracks Sanofi's gene therapy for eye disease GA Sanofi has been granted a speedy review from the FDA for a gene therapy for geographic atrophy, a major cause of blindness.
News Kymera signs $750m cancer deal with Gilead as Sanofi opts in Kymera is celebrating the signing of two partnerships, with Gilead taking an option on one molecular glue programme, as Sanofi buys into another.
News Dupixent is first FDA-approved drug for rare skin disease The long list of therapeutic uses for Sanofi and Regeneron's Dupixent has been lengthened by an FDA approval for rare skin disease bullous pemphigoid.
News Beyfortus now has a direct rival after FDA OK for Enflonsia MSD could soon enter the US market for drugs used to protect infants from RSV infections, setting up a rivalry with AstraZeneca/Sanofi's Beyfortus.
News Sanofi starts shipping RSV drug early as rival nears market As an FDA decision nears from a rival MSD drug, Sanofi is speeding up the rollout of RSV antibody Beyfortus to get ahead of this year's season.
News ASCO 25: Sanofi hopes on-body delivery will boost Sarclisa Can a new on-body injector version of Sanofi's Sarclisa help it claim market share from J&J's rival top-selling Darzalex in multiple myeloma?
News NHS trust rolls out digital health tool for kidney disease An NHS trust in England is starting a pilot study of a digital health platform that promises to improve the care of people with kidney disease.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face